Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
6 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Insmed (NASDAQ: INSM ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Insmed reported strong
The specialist dermatology and oncology company said it achieved first revenues from skin+CELL direct-to-consumer sales and completed a strategic acquisition of Swiss skincare brand énielle. It also said it raised gross proceeds of £355,000 through unsecured convertible loan notes.
Worldsec Limited reported an unaudited net loss of US$490,000 for the six months ended 30 June 2026, versus a loss of US$97,000 a year earlier. The company also said it appointed Elemental Company Secretary Limited as company secretary in September 2026.
Pfizer (NYSE: PFE ) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Full Transcript OPERATOR Good day everyone and wel
AB “Ignitis grupė” (hereinafter — the Group) informs that its Supervisory Board (hereinafter — the Supervisory Board), following a public selection process, approved Vytenis Koryzna as the final candidate for the position of Chair of the Management Board and CEO of the Group.V. Koryzna is currently…
For best results when printing this announcement, please click on link below: RNS Number: 0622W BioPharma Credit PLC 24 September 2026 24 September 2026 BIOPHARMA CREDIT PLC ("BPCR" or "the Company") HALF YEAR REPORT FOR THE YEAR ENDED 30 JUNE 2026 BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt inv